BIM
CTMX icon

Bogle Investment Management’s CytomX Therapeutics CTMX Stock Holding History

Bogle Investment Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-13,500
Closed -$112K – 246
2020
Q2 		$112K Buy
+13,500
New +$125K 0.02% 301
2018
Q4 		– Sell
-32,385
Closed -$599K – 343
2018
Q3 		$599K Sell
32,385
-80,960
-71% -$1.84M 0.04% 232
2018
Q2 		$2.59M Buy
113,345
+8,639
+8% +$221K 0.19% 133
2018
Q1 		$2.98M Sell
104,706
-91,326
-47% -$2.61M 0.22% 122
2017
Q4 		$4.14M Buy
196,032
+32,180
+20% +$667K 0.3% 103
2017
Q3 		$2.98M Buy
+163,852
New +$2.56M 0.2% 138

Other funds holding CTMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bogle Investment Management's CTMX Position: Q3 2020 in Review

Bogle Investment Management sold out of CytomX Therapeutics (CTMX) in Q3 2020, closing a stake of 13,500 shares — an estimated $112K sold.

Bogle Investment Management first reported a position in CTMX in Q3 2017 and held it in 6 quarters. The position peaked at $4.14M in Q4 2017. 130 funds tracked by Wall St. Rank hold CTMX as of Q3 2020.

  • Bogle Investment Management reported no remaining CytomX Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Bogle Investment Management sold 13,500 CytomX Therapeutics shares in Q3 2020, an estimated $112K.
  • Bogle Investment Management first reported a position in CytomX Therapeutics in Q3 2017 and held it in 6 quarters.
  • Bogle Investment Management's CytomX Therapeutics position peaked at $4.14M in Q4 2017.
  • 130 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2020.

Based on Bogle Investment Management's 13F filing for Q3 2020, filed 12 Nov 2020.